Literature DB >> 6813038

Field observations on the antimalarial piperaquine.

L Chen, F Y Qu, Y C Zhou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6813038

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  23 in total

Review 1.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria.

Authors:  Trieu Nguyen Trung; Bo Tan; Dang Van Phuc; Jian-ping Song
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

3.  A small amount of fat does not affect piperaquine exposure in patients with malaria.

Authors:  Anna Annerberg; Khin Maung Lwin; Niklas Lindegardh; Sakchai Khrutsawadchai; Elizabeth Ashley; Nicholas P J Day; Pratap Singhasivanon; Joel Tarning; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

4.  Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children.

Authors:  Melissa D Conrad; Norbert LeClair; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Victor Bigira; Mary Muhindo; Moses R Kamya; Jordan W Tappero; Bryan Greenhouse; Grant Dorsey; Philip J Rosenthal
Journal:  J Infect Dis       Date:  2014-03-08       Impact factor: 5.226

5.  Dictyostelium discoideum expresses a malaria chloroquine resistance mechanism upon transfection with mutant, but not wild-type, Plasmodium falciparum transporter PfCRT.

Authors:  Bronwen Naudé; Joseph A Brzostowski; Alan R Kimmel; Thomas E Wellems
Journal:  J Biol Chem       Date:  2005-05-09       Impact factor: 5.157

6.  Determinants of MDA impact and designing MDAs towards malaria elimination.

Authors:  Bo Gao; Sompob Saralamba; Yoel Lubell; Lisa J White; Arjen M Dondorp; Ricardo Aguas
Journal:  Elife       Date:  2020-04-15       Impact factor: 8.140

7.  Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.

Authors:  Brioni R Moore; Kevin T Batty; Christopher Andrzejewski; Jeffrey D Jago; Madhu Page-Sharp; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

8.  Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.

Authors:  Sant Muangnoicharoen; David J Johnson; Sornchai Looareesuwan; Srivicha Krudsood; Stephen A Ward
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 9.  Clinical features and management of poisoning due to antimalarial drugs.

Authors:  A Jaeger; P Sauder; J Kopferschmitt; F Flesch
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

10.  Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.

Authors:  Badara Cisse; Matthew Cairns; Ernest Faye; Ousmane NDiaye; Babacar Faye; Cecile Cames; Yue Cheng; Maguette NDiaye; Aminata Collé Lô; Kirsten Simondon; Jean-Francois Trape; Oumar Faye; Jean Louis NDiaye; Oumar Gaye; Brian Greenwood; Paul Milligan
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.